Strata Critical Medical Earnings Reports

Strata Critical Medical saw revenue jump 36.7% year-over-year to $49.3 million in Q3 2025. However, net loss widened to $9.7 million due to increased legal and investment-related expenses. Flight profit and margins improved, and the company posted record Medical Segment Adjusted EBITDA.

Blade posted a narrower net loss in Q1 2025, with notable progress in Passenger segment profitability and revenue growth, especially after exiting Canada and restructuring in Europe.

Blade's Q4 2024 revenue grew by 14.5% to $54.4 million, driven by strong performance in the Medical segment. Net loss improved by 71.1% to $9.8 million, and Adjusted EBITDA saw a substantial improvement, reaching near break-even at $(0.4) million. Flight profit increased by 39.7%, with a flight margin expansion to 23.2%.

Blade Air Mobility reported a 4.8% increase in revenue to $74.9 million, driven by growth in the Medical and Short Distance segments. The company achieved positive Passenger Segment Adjusted EBITDA on a trailing twelve-month basis, ahead of schedule. They also announced a strategic alliance with OrganOx to enhance organ transplant logistics.

Blade Air Mobility reported an 11.4% increase in total revenue to $67.9 million, marking its first Adjusted EBITDA positive Q2 as a public company. The Medical and Passenger segments demonstrated strong performance, contributing positive Segment Adjusted EBITDA. The company is reaffirming its guidance for full year 2024, expecting revenue of $240 million to $250 million and positive Adjusted EBITDA.

Blade Air Mobility reported a 13.8% increase in total revenue to $51.5 million, driven by a 34.6% increase in Medical revenue. The company's net loss improved by 58.5% to $(4.2) million, and Adjusted EBITDA improved by 54.1% to $(3.5) million.

Blade Air Mobility reported a 24.5% increase in revenue to $47.5 million for Q4 2023, driven by strong growth in the MediMobility Organ Transport business. The net loss increased to $(33.9) million, primarily due to an impairment charge. Adjusted EBITDA improved to $(5.2) million.